MétaCan
Menu
Back to cohort
Record W4412756476 · doi:10.1016/j.jfma.2025.07.023

Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan

2025· article· en· W4412756476 on OpenAlexaff
Chun‐Jen Liu, Young-Suk Lim, Chi-Yi Chen, Chien-Hung Chen, Yi‐Hsiang Huang, Chun‐Yen Lin, Chun‐Che Lin, Ming‐Lung Yu, Frida Abramov, Leland J. Yee, Ran Duan, John F. Flaherty, Wei‐Wen Su, Sheng‐Shun Yang, Harry L.A. Janssen, Wan‐Long Chuang

Bibliographic record

VenueJournal of the Formosan Medical Association · 2025
Typearticle
Languageen
FieldMedicine
TopicHepatitis B Virus Studies
Canadian institutionsToronto General Hospital
FundersGilead UK and Ireland Corporate ContributionsGilead Sciences
KeywordsMedicineTenofovir alafenamideTenofovirChronic hepatitisVirologyInternal medicineGastroenterologyHepatitis BHuman immunodeficiency virus (HIV)VirusAntiretroviral therapyViral load

Abstract

fetched live from OpenAlex

BACKGROUND/PURPOSE: Tenofovir alafenamide (TAF) has demonstrated non-inferior efficacy to tenofovir disoproxil fumarate (TDF) with improved bone and renal safety across diverse populations, including those with mild renal or hepatic impairment. We evaluated TAF efficacy and safety in a subset of Taiwanese chronic hepatitis B (CHB) patients enrolled in a phase 2, multicentre study (NCT03180619) of patients with more advanced renal or hepatic impairment. METHODS: In a sub-analysis of virally-suppressed (hepatitis B virus DNA <20 IU/mL) adult Taiwanese CHB patients with renal (chronic kidney disease stage ≥1) or hepatic (Child-Turcotte-Pugh Class B or C) impairment, all participants received open-label TAF 25 mg once daily for 96 weeks. Efficacy was evaluated based on proportion of patients with viral suppression and normal alanine aminotransferase levels. Incidence of adverse events (AEs) and laboratory abnormalities were considered over 96 weeks, alongside renal function parameters, hip and spine bone mineral density (BMD) and fasting lipid changes. RESULTS: Of 124 patients treated in the phase 2 study, 33 (27 %) were from Taiwan. All sub-analysis participants (renal impairment, n = 22; hepatic impairment, n = 11) achieved virologic response after 24 weeks of TAF; of the 28 patients who completed the study, 96 % (n = 27) maintained suppression through Week 96. One AE in each group, and no serious AEs, were related to study treatment. Following TAF switch, renal function and BMD remained stable or improved slightly over 96 weeks. CONCLUSION: Consistent with overall population results, TAF demonstrated high efficacy and favourable safety and tolerability in Taiwanese CHB patients with renal or hepatic impairment. TRIAL REGISTRATION: NCT03180619/GS-US-320-4035.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.031
Threshold uncertainty score0.984

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.265
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Formosan Medical AssociationSame topicHepatitis B Virus StudiesFrench-language works237,207